Skip to main content
. 2021 Sep 8;148(5):1176–1191. doi: 10.1016/j.jaci.2021.08.021

Fig 1.

Fig 1

IHG associations in study cohorts. A and B, IHG features. Ratio, CD4:CD8 ratio. C,Left: IHG prevalence in SardiNIA cohort by sex and age strata and females with SLE. Middle: IHG at presentation in the COVID-19 cohort by sex, hospitalization and survivor status, and nonsurvivors by age. Right: IHG in therapy-naive HIV+ participants (with known dates of seroconversion) at entry into the Natural History Study by entry viral load (VL; <1K, 1-10K, 10-100K, ≥100K copies/mL; K, ×103). Rightmost: IHGs before and after at least 5 years of antiretroviral therapy (ART). D, IHG prevalence (top) and OR with 95% CI for prevalence of IHG-I (bottom) by sex within age strata. E, HRs with 95% CI of developing AIDS (1987 criteria51) in HIV+ participants by entry IHG. H, High; L, low. F,Top-left: IHG prevalence by age strata. PIHG-I and PIHG-IV is for the proportion of IHG-I vs rest and IHG-IV vs rest across age strata. Top-right: Age strata distribution by IHG subgrades. Middle-left and right: OR with 95% CI for hospitalization. OR by age strata (left) adjusted by baseline IHG status and OR by baseline IHG status (right) adjusted by age strata. Bottom: Median values of CD4+ and CD8+ counts and CD4:CD8 ratio by hospitalization status (yes/no) and (left) age strata and (right) IHG subgrades. F, Female; M, male. †P = .06. ∗P < .05. ∗∗P < .01. ∗∗∗P < .001.